Apparently, the VPS9D1-AS1-miR-532-3p-HMGA2 pathway is important for the malignant manifestations of NSCLC, which makes it an attractive target for NSCLC therapy. This evidence concerns the gene VPS9D1 and non-small cell lung carcinoma.